FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4313331792> ?p ?o ?g. }

• W4313331792 endingPage "10" @default.
• W4313331792 startingPage "1" @default.
• W4313331792 abstract "Esophageal squamous cell cancer (ESCC) is a deadly malignant tumor characterized by an overall 5-year survival rate below 20%, with China accounting for approximately 50% of all cases worldwide. Our previous studies have demonstrated that high integrin-linked kinase (ILK) expression plays a key role in development and progression of ESCC both in vitro and in vivo. Here, we employed the drug repurposing approach to identify a novel FDA-approved anticancer inhibitor against ILK-induced tumorigenesis and progression.We screened the ZINC15 database and predicted the molecular docking ability among FDA-approved and publicly available drugs to ILK and then performed computational docking and visual inspection analyses of the top 10 ranked drugs. Two computer-based virtual screened drugs were evaluated in vitro for their ability to directly bind purified ILK by surface plasmon resonance. Cytotoxicity of the two candidate drugs was validated in vitro using CCK-8 and LDH assays.We initially selected the top 10 compounds, based on their minimum binding energy to the ILK crystal, after molecular docking and subjected them to further screening. Taking the binding energy of -10 kcal/mol as the threshold, we selected two drugs, namely, nilotinib and teniposide, for the wet-lab experiment. Surface plasmon resonance (SPR) revealed that nilotinib and teniposide had equilibrium dissociation constant (KD) values of 6.410E - 6 and 1.793E - 6, respectively, which were lower than 2.643E - 6 observed in ILK-IN-3 used as the positive control. The IC50 values for nilotinib and teniposide in ESCC cell lines were 40 μM and 200-400 nM, respectively. Results of the CCK-8 assay demonstrated that both nilotinib and teniposide significantly inhibited proliferation of cells (P < 0.01). LDH results revealed that both drugs significantly suppressed the rate of cell death (P < 0.01).The drug repositioning procedure can effectively identify new therapeutic tools for ESCC. Our findings suggest that nilotinib and teniposide are efficacious inhibitors of ILK and thus have potential to target ILK-mediated signaling pathways for management of ESCC." @default.
• W4313331792 created "2023-01-06" @default.
• W4313331792 creator A5004155401 @default.
• W4313331792 creator A5027305986 @default.
• W4313331792 creator A5029496793 @default.
• W4313331792 creator A5029801284 @default.
• W4313331792 creator A5047282437 @default.
• W4313331792 creator A5050271178 @default.
• W4313331792 creator A5062662220 @default.
• W4313331792 creator A5074529547 @default.
• W4313331792 date "2022-12-29" @default.
• W4313331792 modified "2023-10-10" @default.
• W4313331792 title "Computational Drug Repurposing Approach to Identify Novel Inhibitors of ILK Protein for Treatment of Esophageal Squamous Cell Carcinoma" @default.
• W4313331792 cites W1757990252 @default.
• W4313331792 cites W1854810044 @default.
• W4313331792 cites W1972105230 @default.
• W4313331792 cites W2012899108 @default.
• W4313331792 cites W2024873935 @default.
• W4313331792 cites W2041729187 @default.
• W4313331792 cites W2060136332 @default.
• W4313331792 cites W2068585362 @default.
• W4313331792 cites W2105668062 @default.
• W4313331792 cites W2106612397 @default.
• W4313331792 cites W2139942857 @default.
• W4313331792 cites W2163816950 @default.
• W4313331792 cites W2164088236 @default.
• W4313331792 cites W2180898434 @default.
• W4313331792 cites W2747732442 @default.
• W4313331792 cites W2787849300 @default.
• W4313331792 cites W2793002686 @default.
• W4313331792 cites W2807730915 @default.
• W4313331792 cites W2895370006 @default.
• W4313331792 cites W2896002881 @default.
• W4313331792 cites W2951512731 @default.
• W4313331792 cites W2969997266 @default.
• W4313331792 cites W2971801381 @default.
• W4313331792 cites W2979423749 @default.
• W4313331792 cites W2989839786 @default.
• W4313331792 cites W2989943253 @default.
• W4313331792 cites W2998322952 @default.
• W4313331792 cites W3001430437 @default.
• W4313331792 cites W3024994706 @default.
• W4313331792 cites W3083607087 @default.
• W4313331792 cites W3119368005 @default.
• W4313331792 cites W3119657489 @default.
• W4313331792 cites W3125741175 @default.
• W4313331792 cites W3128646645 @default.
• W4313331792 cites W3160612836 @default.
• W4313331792 cites W3164806714 @default.
• W4313331792 cites W3207872638 @default.
• W4313331792 cites W4207062021 @default.
• W4313331792 cites W4214669832 @default.
• W4313331792 cites W4255677297 @default.
• W4313331792 cites W4280507319 @default.
• W4313331792 cites W4283742284 @default.
• W4313331792 doi "https://doi.org/10.1155/2022/3658334" @default.
• W4313331792 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36618074" @default.
• W4313331792 hasPublicationYear "2022" @default.
• W4313331792 type Work @default.
• W4313331792 citedByCount "1" @default.
• W4313331792 crossrefType "journal-article" @default.
• W4313331792 hasAuthorship W4313331792A5004155401 @default.
• W4313331792 hasAuthorship W4313331792A5027305986 @default.
• W4313331792 hasAuthorship W4313331792A5029496793 @default.
• W4313331792 hasAuthorship W4313331792A5029801284 @default.
• W4313331792 hasAuthorship W4313331792A5047282437 @default.
• W4313331792 hasAuthorship W4313331792A5050271178 @default.
• W4313331792 hasAuthorship W4313331792A5062662220 @default.
• W4313331792 hasAuthorship W4313331792A5074529547 @default.
• W4313331792 hasBestOaLocation W43133317921 @default.
• W4313331792 hasConcept C103637391 @default.
• W4313331792 hasConcept C103697762 @default.
• W4313331792 hasConcept C121608353 @default.
• W4313331792 hasConcept C126322002 @default.
• W4313331792 hasConcept C150903083 @default.
• W4313331792 hasConcept C159110408 @default.
• W4313331792 hasConcept C207001950 @default.
• W4313331792 hasConcept C2777413986 @default.
• W4313331792 hasConcept C2777583451 @default.
• W4313331792 hasConcept C2778019345 @default.
• W4313331792 hasConcept C2778695046 @default.
• W4313331792 hasConcept C2778729363 @default.
• W4313331792 hasConcept C2780035454 @default.
• W4313331792 hasConcept C29537977 @default.
• W4313331792 hasConcept C41685203 @default.
• W4313331792 hasConcept C502942594 @default.
• W4313331792 hasConcept C60644358 @default.
• W4313331792 hasConcept C66417403 @default.
• W4313331792 hasConcept C71924100 @default.
• W4313331792 hasConcept C74187038 @default.
• W4313331792 hasConcept C82495950 @default.
• W4313331792 hasConcept C86803240 @default.
• W4313331792 hasConcept C98274493 @default.
• W4313331792 hasConceptScore W4313331792C103637391 @default.
• W4313331792 hasConceptScore W4313331792C103697762 @default.
• W4313331792 hasConceptScore W4313331792C121608353 @default.
• W4313331792 hasConceptScore W4313331792C126322002 @default.
• W4313331792 hasConceptScore W4313331792C150903083 @default.

• next